Plymouth Meeting biotech company Inovio’s innovations are paying off. Amid positive feedback from the FDA on an experimental respiratory disease therapy, the Montgomery County-based company’s shares soared more than 11 percent, writes John George for the Philadelphia Business Journal.  

The therapy specifically treats recurrent respiratory papillomatosis (RRP), a rare disease that causes non-cancerous tumors to grow in the body’s air passages. This disease impacts around 20,000 people within the United States, according to the RRP Foundation.

This condition can lead to difficulties with breathing and swallowing. For now, the primary treatment is surgery. However, Inovio’s recently submitted clinical trial data for INO-3107 has been highly lauded by the federal agency.  

The submitted data on the experimental drug could support the company’s submission of a biologics license application to get accelerated approval. 

If this treatment gets the green light, INO-3107 could be the first DNA medicine in the country.  

“We believe INO-3107 could become a game-changing treatment option for those suffering from RRP, a serious and often difficult-to-treat disease,” said Inovio CEO Dr. Jacqueline Shea. 

 Read more about this groundbreaking therapy that is the first of its kind, and how the biotech company behind it is skyrocketing in the Philadelphia Business Journal.  

DNA Medicines for Recurrent Respiratory Papillomatosis